摘要
目的分析肺结核患者对吡嗪酰胺的耐药情况,为防治提供参考。方法采用WHO推荐的BACTEC MGIT-960系统法对218例涂阳肺结核进行吡嗪酰胺耐药性检测分析。结果 218例涂阳肺结核中耐吡嗪酰胺39例(17.9%)。其中163例初治患者耐吡嗪酰胺23例(14.1%),55例复治患者耐吡嗪酰胺16例(29.1%);91例耐多药((multi-drug-resistant,MDR)患者耐吡嗪酰胺36例(39.6%),127例非MDR患者耐吡嗪酰胺3例(2.4%)。复治患者吡嗪酰胺耐药率明显高于初治患者(P<0.05),MDR患者吡嗪酰胺耐药率明显高于非MDR患者(P<0.01)。结论 MDR肺结核耐吡嗪酰胺率较高,应重视对MDR肺结核的吡嗪酰胺耐药性检测,以便采用更合理有效的方案治疗之。
The aim is to explore pyrazinamide（PZA） resistance situation in patients with smear positive pulmonary tuberculosis and provide reference for TB control and treatment in clinic.The BACTEC MGIT 960 system was used to conduct susceptibility test of Mycobacterium tuberculosis isolates to PZA in 218 smear positive pulmonary tuberculosis patients.Results showed that 39 cases were PZA-resistant by the test,and the total PZA resistance rate was 17.9%.For 163 new cases with tuberculosis,23 were PZA-resistant（14.1%）.In addition,16 out of 55 re-treated cases and 36 out of 91 MDR cases were PZA-resistant,with the rates of 29.1% and 39.6%,respectively.Moreover,three of 127 non-MDR cases were PZA-resistant,with a rate of 2.4%.The PZA resistance rate in re-treated cases was higher than that of new cases（P0.05）,and the rate in MDR cases was obviously higher than that of non-MDR cases（P0.01）.It＇s suggested that more importance should be attached to the PZA susceptibility test in MDR patients,and the reasonable and effective therapy could be selected for MDR-TB.
出处
《中国人兽共患病学报》
CAS
CSCD
北大核心
2012年第10期1000-1002,共3页
Chinese Journal of Zoonoses
基金
国家科技重大专项(2008ZX10003-004)
中国全球基金福建省结核病控制项目
世行贷款/英国赠款福建省结核病控制项目(卫十项目)~~
关键词
肺结核
耐药性
吡嗪酰胺
pulmonary tuberculosis
susceptibility
pyrazinamide
